Finding Hidden Myeloma Using IMMunoPET Imaging Technology | Ola Landgren, MD, PhD

Bispecific Antibodies in CNS Myeloma: What Patients Should Know | Mahmoud Gaballa, MD

Bispecific Antibodies in CNS Myeloma: What Patients Should Know | Mahmoud Gaballa, MD

Real-world Data on patients being treated with teclistamab | Artur Jurczyszyn, MD

Real-world Data on patients being treated with teclistamab | Artur Jurczyszyn, MD

Living Longer With Myeloma: Real-World Clinic Results | James Berenson, MD

Living Longer With Myeloma: Real-World Clinic Results | James Berenson, MD

An Overview of the Most Recent Studies in Multiple Myeloma | Claudio Cerchione, MD, PhD

An Overview of the Most Recent Studies in Multiple Myeloma | Claudio Cerchione, MD, PhD

Daratumumab + lenalidomide vs lenalidomide as myeloma maintenance | Mitul Gandhi, MD

Daratumumab + lenalidomide vs lenalidomide as myeloma maintenance | Mitul Gandhi, MD

Updates on Ramantamig, a Myeloma Trispecific Antibody | Mark Wildgust, PhD

Updates on Ramantamig, a Myeloma Trispecific Antibody | Mark Wildgust, PhD

Why Some Newly Diagnosed Myeloma Patients Don’t Reach a Deep Response |Jonathan Kaufman, MD

Why Some Newly Diagnosed Myeloma Patients Don’t Reach a Deep Response |Jonathan Kaufman, MD

Multidisciplinary approaches to improve prognosis prediction | Claudio Cerchione, MD, PhD

Multidisciplinary approaches to improve prognosis prediction | Claudio Cerchione, MD, PhD

Amyloidosis and immune profling in AL and ATTR amyloidosis | Philip McCarthy, MD